16 January, 2023
Qrem and Creatio will develop a protocol to isolate monocytes – MONOCOL project, INNOTEC grant – ACCIÓ (Advanced Therapies)
QREM REGENERATIVE TECHNOLOGY TOGETHER WITH CREATIO UB WILL DEVELOP AN INNOVATIVE PROTOCOL TO ISOLATE IMMUNE SYSTEM CELLS
The Catalan start-up Qrem Regenerative Technology has trusted with Creatio UB TECNIO Center to jointly develop the MONOCOL project (New MONOcyte isolation protoCOL for therapeutic applications at the patient’s side). This innovative project has received funding through the INNOTEC grant awarded by ACCIÓ – Agency for Business Competitiveness.
The project will create a new protocol to isolate cells in a closed system, under conditions of Good Manufacturing Practice (GMP) and without the need to use complex equipment or personnel with specific training. The new protocol will focus on the isolation of monocytes, cells of the immune system involved in tissue repair and regeneration. The developed protocol will solve most of the disadvantages of the procedures to purify monocytes. The new protocol will increase monocyte recovery yield, avoid the use of toxic reagents, decrease blood volume for the sampling tests, reduce isolation time, among others. These improvements will allow that the device can be easily implemented in hospitals, and thus improving accessibility for patients.
To achieve this milestone, it requires the collaboration of a multidisciplinary team, from highly qualified personnel that work in clean rooms to biomedical engineers. From Creatio Maria Camanyes, quality control technician, and from the start-up Àlex Arqué, industrial doctorate student (partly financed by Generalitat de Catalunya), are in charge of designing the experiments and test them under GMP. The results of this study will allow Qrem Regenerative Technology to expand its product catalogue by offering a new health product. On the other hand, Creatio will be able to incorporate new protocols and new therapeutic strategies in its facilities, as well as in hospitals, next to the patient. This will allow them to offer more personalized and cost-effective services.
Qrem Regenerative Technology is a regenerative medicine start-up founded in 2016 focused on autologous regenerative therapies alongside the patient. The start-up develops, manufactures and markets medical devices. The company’s first product on the market in 2019 is Qrem Cytokine is, and it allows to obtain a Serum Rich in Cytokines from the patient’s blood that is infiltrated locally in the area to be treated.
Creatio, the academic center for the production and validation of advanced therapies of the University of Barcelona accredited by TECNIO and with GMP and ISO9001:2015 certifications, offers solutions based on advanced therapies to increase the efficiency of the healthcare system and improve the quality of life of the society.